Argenx SE (NASDAQ: ARGX ) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results